

Press release

Stockholm February 8, 2022

## Bactiguard will publish its year-end report for 2021 tonight at 23.00

Following the announcement of the expanded partnership with Zimmer Biomet, Bactiguard has decided to publish the year-end report for 2021 tonight at 23.00 CET, instead of on Thursday February 10, as earlier announced.

An audiocasted presentation will take place on Wednesday February 9 at 15.00 CET. Bactiguard's CEO Anders Göransson and CFO Gabriella Björknert Caracciolo will present the year-end report, comment on the expanded global partnership and answer questions. The presentation will be held in English.

**To participate in the audiocast, please use this link:**

[www.bactiguard.com/Q4-2021](http://www.bactiguard.com/Q4-2021)

**To participate only by conference call, dial:**

SE: +46850558351, UK: +443333009261, US: +16467224904

Questions can be asked either in writing via the audiocast or orally if you attend the conference call.

**For further information, please contact:**

Gabriella Björknert Caracciolo, CFO and deputy CEO, phone: +46 72 141 62 49

### About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with the Bactiguard technology are market leading in the USA and Japan through our licensing partner BD, and in 2021 orthopaedic trauma implants, ZNN Bactiguard, were launched by Zimmer Biomet. Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills microbes while being biocompatible and tissue friendly.

Bactiguard is in a strong expansion phase in the markets in Europe, China, India, the Middle East and Southeast Asia through our own product portfolio and by establishing licensing deals in new therapy areas. Bactiguard has about 210 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.



# Bactiguard®

Read more about Bactiguard [www.bactiguard.com](http://www.bactiguard.com)

